The P2X7 receptor as a new pharmacological target for retinal diseases
Chiara Bianca Maria Platania1, Filippo Drago2, Claudio Bucolo2
1Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy.
Abstract:
Purinergic ionotropic receptors, such as the P2X7 receptor, are activated by extracellular adenosine triphosphate (ATP). The P2X7 receptor is a trimeric ATP-gated cation channel and its activation results in several downstream events, including the release of proinflammatory mediators and cell damage. The P2X7 receptor has been studied as a pharmacological target for inflammatory and neuroinflammatory diseases, and preclinical studies have recently provided evidence that P2X7 receptor activation is implicated in pathophysiology of several retinal age-related diseases. These diseases are devastating conditions that have an deep impact on the quality of life of patients and on the health systems of all countries. In this review, we discuss the role of the P2X7 receptor in retinal age-related conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Furthermore, we focus on the pharmacological modulation of the P2X7 receptor that could have a relevant clinical impact to prevent retinal diseases.
Insights
The P2X7 receptor, activated by adenosine triphosphate (ATP), plays a key role in age-related retinal diseases like glaucoma and macular degeneration. Targeting this receptor may offer new treatments for these vision-impairing conditions.
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Background:
- Purinergic ionotropic receptors, specifically the P2X7 receptor, are activated by extracellular adenosine triphosphate (ATP).
- P2X7 receptor activation triggers downstream events, including the release of proinflammatory mediators and cellular damage.
- The P2X7 receptor is a known pharmacological target for inflammatory and neuroinflammatory diseases.
Purpose of the Study:
- To review the role of the P2X7 receptor in the pathophysiology of age-related retinal diseases.
- To discuss the potential of P2X7 receptor modulation as a therapeutic strategy for retinal conditions.
Main Methods:
- Literature review focusing on preclinical studies and existing research.
- Analysis of the P2X7 receptor's involvement in glaucoma, age-related macular degeneration, and diabetic retinopathy.
- Exploration of pharmacological approaches targeting the P2X7 receptor.
Main Results:
- Preclinical evidence indicates P2X7 receptor activation is implicated in the pathology of several age-related retinal diseases.
- The P2X7 receptor's role in conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy is highlighted.
- Pharmacological modulation of the P2X7 receptor shows promise for clinical applications.
Conclusions:
- The P2X7 receptor is a significant factor in the development of age-related retinal diseases.
- Targeting the P2X7 receptor presents a potential therapeutic avenue for preventing or treating these devastating conditions.
- Further research into P2X7 receptor modulation could lead to significant clinical advancements in ophthalmology.
